worthy read from tech guru, page-5

A few comments on recent and future newsflow.

1.Two excellent articles posted here in recent days imo. 'Seeking Alpha' from Nuts (post # 9575582, reposted today by timoh) and the German interview with Prima's CFO Marc Voigt posted by 20521. (post # 9575336)

I had the opportunity to meet Mr Voigt at one of the investor briefings earlier this year. Like a lot of money men, he impressed me as a fairly conservative type. So I couldn't help but note the positivity in some of his recent comments:

a.On the risk vs reward profile of the company:
"the risk accordingly, the gains can be enormous"

b.And his estimate of the market potential of Cvac, given trial success:
"....clearly in the three-digit million euro range estimate annually."

Worth reading the article if you haven't already.
..........................................................

2. Tuesday's update will be interesting, but the data release in Amsterdam on October 1st is pivotal imo. So I'm a little surprised that the company has chosen a conference where they only get a 12 minute slot.

Must be all they need.
...........................................................

3. Like a few others here I'm interested to know what proportion of total equity is in foreign hands. The equivalent of 5+million shares traded overnight in ADR's is a great sign imo.

Wondering how many of those are new sales by the market maker, and how many are churned. I'm hoping the shareholders info section of the annual report will give a clue? It might be the equivalent of 'selling the farm', but I think the level of US ownership may in the long term correlate with market cap.
...........................................................

4.Investing in the biotech sector can be a tough gig. Everyone’s looking for an edge. With varying success over the years, I try to read the signals from a company prior to key data releases.

I've found directors committing their hard earned to be a good guide. But advance booking of high profile (post data) speaking engagements can be another. With that in mind I'm encouraged to see Matthew Lehmann listed among a panel of very heavy hitters, addressing the New York Academy of Science on October 28th.

According to the website, “This symposium will highlight recent clinical trial results and provide a biotech perspective on the remaining bottlenecks and roadblocks that must be solved in order for DC therapy to be successfully commercialized.”

I don't think ML would accept this engagement if he thought he might have to stand in the spotlight and say 'Sorry, ours doesn’t work.'

This symposium addresses issues that regularly excite debate in HC. Worthy of a company webcast imo.

http://www.nyas.org/Events/Detail.aspx?cid=1c438f07-d882-495b-aba1-0f59ee385a26

Have a good weekend. Herro